YARTEMLEA is approved by the U.S. FDA for the treatment of TA-TMA in adults and in children ages two years and older. A marketing authorization application for YARTEMLEA for TA-TMA is under review by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback